7 years of historical data (2019–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Recursion Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.9B | $1.8B | $1.9B | $2.0B | $1.4B | $2.9B | — | — |
| Enterprise Value | $1.3B | $1.2B | $1.4B | $1.7B | $854M | $2.6B | — | — |
| P/E Ratio → | -2.55 | — | — | — | — | — | — | — |
| P/S Ratio | 25.96 | 24.50 | 31.50 | 46.71 | 34.11 | 291.68 | — | — |
| P/B Ratio | 1.45 | 1.62 | 1.79 | 4.42 | 2.79 | 5.37 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 15.60 | 23.25 | 38.94 | 21.53 | 264.31 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Recursion Pharmaceuticals, Inc. earns an operating margin of -867.9%. Operating margins have compressed from -797.8% to -867.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -59.5% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 5.0% | 5.0% | 23.1% | 2.9% | -21.7% | 100.0% | 100.0% | -2577.3% |
| Operating Margin | -867.9% | -867.9% | -814.1% | -797.8% | -619.3% | -1827.8% | -2479.2% | -3649.4% |
| Net Profit Margin | -863.4% | -863.4% | -788.0% | -747.7% | -603.5% | -1864.8% | -2549.3% | -3654.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -59.5% | -59.5% | -61.9% | -69.1% | -46.6% | -110.8% | — | — |
| ROA | -44.1% | -44.1% | -44.1% | -48.4% | -36.5% | -41.0% | -43.5% | -61.6% |
| ROIC | -95.8% | -95.8% | -107.0% | -479.8% | -143.9% | — | — | — |
| ROCE | -50.1% | -50.1% | -52.6% | -60.3% | -42.2% | -43.6% | -45.7% | -65.9% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $743M exceeds total debt of $78M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.10 | 0.11 | 0.10 | 0.02 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.59 | -0.47 | -0.74 | -1.03 | -0.50 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -358.08 | -358.08 | -304.71 | -3608.87 | -4467.76 | -61.92 | -62.22 | -98.33 |
Net cash position: cash ($743M) exceeds total debt ($78M)
Short-term solvency ratios and asset-utilisation metrics
Recursion Pharmaceuticals, Inc.'s current ratio of 5.50x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.70x to 5.50x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.50 | 5.50 | 3.81 | 4.70 | 5.68 | 11.46 | 11.53 | 11.43 |
| Quick Ratio | 5.50 | 5.50 | 3.81 | 4.70 | 5.68 | 11.46 | 11.53 | 11.43 |
| Cash Ratio | 5.03 | 5.03 | 3.17 | 4.20 | 5.48 | 11.07 | 11.35 | 10.46 |
| Asset Turnover | — | 0.05 | 0.04 | 0.07 | 0.06 | 0.02 | 0.01 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 120.47 | 304.99 | 25.74 | 25.32 | 331.79 | 16.68 | 32.21 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Recursion Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $447M | $274M | $208M | $176M | $170M | $166M | $166M |
Compare RXRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| RXRXYou | $2B | -2.5 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
| REGN | $108B | 18.8 | 21.6 | 26.4 | 86.3% | 25.7% | 14.9% | 12.4% | 0.6 |
| CNTA | $4B | -13.0 | — | — | — | — | -73.9% | -91.8% | — |
| IMNM | $2B | -4.4 | — | — | 100.0% | -3382.4% | -194.6% | -700.3% | — |
| CLDX | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| NRIX | $2B | -5.2 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
| ROIV | $1B | -120.6 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
| ABCL | $1B | -7.4 | — | — | — | -289.0% | -14.5% | -16.8% | — |
| ARVN | $975M | -10.4 | — | — | -151.8% | -45.1% | -16.2% | -23.1% | — |
| XNCR | $918M | -10.3 | — | — | — | — | -9.5% | — | — |
| TECX | $439M | -6.0 | — | — | — | — | -206.6% | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 7 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how RXRX stacks up against sector leader Regeneron Pharmaceuticals, Inc..
Start ComparisonRecursion Pharmaceuticals, Inc.'s current P/E ratio is -2.5x. This places it at the 50th percentile of its historical range.
Recursion Pharmaceuticals, Inc.'s return on equity (ROE) is -59.5%. The historical average is -69.6%.
Based on historical data, Recursion Pharmaceuticals, Inc. is trading at a P/E of -2.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Recursion Pharmaceuticals, Inc. has 5.0% gross margin and -867.9% operating margin.